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Abstract
Background: Understanding the mechanisms underlying viral control is highly relevant to vaccine studies and elite control
(EC) of HIV infection. Although numerous definitions of EC exist, it is not clear which, if any, best identify this rare
phenotype.
Methods: We assessed a number of EC definitions used in the literature using CASCADE data of 25,692 HIV seroconverters.
We estimated proportions maintaining EC of total ART-naı¨ve follow-up time, and disease progression, comparing to non-EC.
We also examined HIV-RNA and CD4 values and CD4 slope during EC and beyond (while ART naı¨ve).
Results: Most definitions classify ,1% as ECs with median HIV-RNA 43–903 copies/ml and median CD4.500 cells/mm3.
Beyond EC status, median HIV-RNA levels remained low, although often detectable, and CD4 values high but with strong
evidence of decline for all definitions. Median % ART-naı¨ve time as EC was $92% although overlap between definitions was
low. EC definitions with consecutive HIV-RNA measurements ,75 copies/ml with follow-up$ six months, or with 90% of
measurements ,400 copies/ml over $10 year follow-up preformed best overall. Individuals thus defined were less likely to
progress to endpoint (hazard ratios ranged from 12.5–19.0 for non-ECs compared to ECs).
Conclusions: ECs are rare, less likely to progress to clinical disease, but may eventually lose control. We suggest definitions
requiring individuals to have consecutive undetectable HIV-RNA measurements for $ six months or otherwise with .90%
of measurements ,400 copies/ml over $10 years be used to define this phenotype.
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Introduction
HIV is typically characterised by a period of viral replication
and CD4 cell decline leading to AIDS and death in the absence of
antiretroviral therapy (ART). [1] Differences in the evolution of
both markers over time, however, result in large variations in
disease progression among HIV-positive individuals. [2,3] The
long-term non-progressor (LTNP) phenotype was initially de-
scribed to characterise individuals who experienced slow disease
progression and stable CD4 counts over a number of years. [4,5]
With the introduction of HIV-RNA assays in the mid-1990s,
research shifted to focus on mechanisms which lead to control of
viral replication [6].
A small proportion of individuals have been described who are
able to suppress viral replication to undetectable levels for
extended periods of time without use of ART, delaying the onset
of AIDS. [7,8] Many terms are used in the literature for such
individuals, with the most common being elite controllers (EC). [8]
Mechanisms of EC remain unclear, although it is now believed
that host response, including CD4 and CD8 T cell-specific
immune response, [9,10] as well as HLA Class I alleles, [11] are
likely to be the main mechanisms of control, rather than infection
by defective virus, as initially postulated. [12] Whatever the
mechanisms, a study of this group of individuals gives potential for
the development of new treatment strategies, can guide research
on HIV vaccines,[13–16] and provide models for a functional cure
of HIV [17,18].
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Since the publication of initial definitions of EC, as was the case
with the long-term non-progressor (LTNP) phenotype, many more
definitions have been proposed; presumably to arrive at one
definition which best defines true EC. There are currently
numerous definitions, each of which differs by the follow-up time
required and the number and threshold of undetectable HIV-
RNA measurements.[6–8,15,16,19–23] It is not known which, if
any, best characterise this rare phenotype, however. This is
important to ensure that any difference between elite controllers
and non-controllers can be attributed to the phenotype itself. An
assessment of the relative merits of each definition has never been
undertaken or a comparison between them preformed.
The CASCADE (Concerted Action on SeroConversion on
AIDS and Death in Europe) Collaboration, of HIV-positive
individuals followed-up since HIV seroconversion, offers a unique
opportunity to assess the ability of these definitions to capture EC.
Using data from CASCADE, we aimed to evaluate a number of
commonly-used definitions to estimate prevalence of EC and
associated factors, proportion of total follow-up time spent as elite,
and to describe CD4 and HIV-RNA values during EC and
beyond the EC period.
The work provides the basis for choosing a definition
appropriate to the objectives of future research on this rare
phenotype.
Materials and Methods
Study Population
We used pooled data from the CASCADE September 2011
data release in EuroCoord (www.EuroCoord.net), which consists
of 25,629 seroconverters from 28 cohorts across Europe, Canada,
Australia and sub-Saharan Africa. [24] Date of seroconversion is
estimated by various methods, most commonly as the midpoint
between the last documented HIV negative and the first positive
HIV antibody test dates with an interval of ,3 years between the
two test dates (85%). For the remainder, date of seroconversion
was estimated through laboratory evidence of seroconversion
(PCR positivity in the absence of HIV antibodies or antigen
positivity with fewer than four bands on Western blot) (13%), or as
the date of a seroconversion illness (2%) with both an earlier
documented negative and a later positive HIV test not more than
3 years apart. Anonymized data for the CASCADE collaboration
are collected and stored at the Medical Research Council Clinical
Trials Unit at University College London. Access is available to
bona fide researchers through submission of a proposal to the
Steering Committee which is reviewed by CASCADE investiga-
tors.
Elite Control Definitions
We undertook a systematic review of the literature, which is
described elsewhere [25]. Briefly, we searched for terms previously
used to describe control of HIV infection including ‘‘Long term
non-progressors’’, ‘‘LTNP’’, ‘‘elite controller’’, ‘‘elite control’’,
‘‘viral controller’’ and ‘‘viral control’’ and evaluated 10 EC
definitions (Table 1).[6–8,15,16,19–23] The list of definitions
included in this paper is not intended to be exhaustive; rather it is
representative of the spectrum by which the elite control
phenotype is defined in the literature. Three definitions were
most commonly used, all requiring HIV positive individuals to
meet the following criteria while ART-naive and AIDS-free: 1)
Definition E, used by the International HIV Controllers Consor-
tium, of individuals who maintain HIV-RNA levels below 75
copies/mL for at least 1 year, [8] 2) Definition F, an adaptation of
definition E allowing no previous HIV-RNA levels .1000 copies/
ml, [6] and 3) Definition J, initially proposed by the ANRS, of
individuals known to be HIV positive for$10 years with$2 HIV-
RNA measurements, $90% of which were required to be ,400
copies/ml [7].
Statistical Methods
We identified three groups of individuals for each definition:
those who fulfilled it, those who did not, and those whose EC
status could not be determined, e.g. because insufficient follow-up
or ART-naive HIV-RNA measurements were not available. For
each definition we estimated the proportion of EC excluding
individuals whose EC status was unknown from the denominator.
Because there were large numbers with unknown status, we also
estimated proportion of EC by assuming them to be non-EC and
including them in the denominator, thus providing minimum
proportion estimates.
For each definition we estimated the proportion of time they
remained as EC by considering all available ART-naive follow-up.
To estimate the effect of EC status on disease progression we
restricted entry to the risk set at 10 years post seroconversion, as
this was the longest duration of follow-up required by all
definitions considered, and used multivariable time dependent
Cox proportional hazards models to estimate the hazard ratio for a
Table 1. 10 definitions of elite control from the literature applied to the CASCADE dataset; all require individuals to be AIDS-free
and ART-naı¨ve.
Definition
A HIV-positive $6 months, with $2 consecutive HIV-RNA ,75 copies/ml [22]
B HIV-positive $1 year, with $1 HIV-RNA ,50 copies/ml [16]
C HIV-positive $1 year, with $1 HIV-RNA ,75 copies/ml [15]
D HIV-positive $1 year, with $3 HIV-RNA ,2000 copies/ml [21]
E HIV-positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months [8]
F HIV-positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months with no previous blips $1000 copies/ml [6]
G HIV-positive $2 years, with $2 HIV-RNA ,75 copies/ml [19]
H HIV-positive $5 years, with $5 consecutive HIV-RNA ,500 copies/ml [23]
I HIV-positive $10 years, with all measured HIV-RNA ,50 copies/ml [20]
J HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml [7]
doi:10.1371/journal.pone.0086719.t001
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composite endpoint of AIDS, death (all cause), ART initiation or
CD4,350 cells/mm3 comparing non-ECs and unknowns to ECs.
We formally tested differences in hazard ratios between the
definitions by using 1000 bootstrap replicates. Definition I was
excluded from the bootstrap analysis as there were few follow-up
measurements among a small number of elite controllers providing
unstable estimates.
We described median and interquartile ranges (IQR) of HIV-
RNA and CD4 levels, based on median individual values, while
classified as EC and during total ART-naı¨ve follow-up time. CD4
slopes were estimated using a linear mixed model on the square
root scale, while classified as an elite controller, and also during
total ART-naı¨ve follow-up time.
Results
Data from 28 cohorts of 25,692 individuals formed the base
from which sub-populations of EC and non-EC were drawn
according to each definition. Median (IQR) year of HIV
seroconversion was 1999 (1992, 2005) and median age at
seroconversion 31 years (25, 37). HIV risk groups were MSM
(55%), MSW (26%) or IDU (14%), and the majority were male
(78%).
Proportion Classified as EC and Patient Characteristics
The proportion classified as EC by each definition was 0.15–
7.70% and did not necessarily reflect the length of follow-up
required by the definition (Table 2). While variations in age, sex
and risk group were observed for each definition, no consistent
differences were observed across definitions.
The number of individuals fulfilling two definitions was
generally low with 33% of individuals overlapping by ,30% with
another definition (Table 3).
Total Time Spent as EC
The risk of composite endpoint was consistently significantly
higher for non-EC/unknown compared to ECs for all definitions,
with hazard ratios ranging from 2.9–19.0 and being greatest for
definitions A, E, F and J (Table 4). 1000 bootstrap replicates
confirmed the superiority of A, E and F (a= 0.05) above
definitions B, C, D, G and H, the former 3 definitions not being
statistically different from each other. Definition J was not
statistically superior to any other definition.
Considering all available ART-naı¨ve follow-up from serocon-
version, the proportion of time spent as EC, according to each
definition, was remarkably high with median follow-up$92% for
all definitions, although 25% of EC, according to definitions C, D
and F, spent #72% of their ART-naı¨ve follow-up time as EC
(Table 4). Figure 1 illustrates total ART-naive follow-up for all
individuals classified as EC by definitions A, E, F, and J.
HIV-RNA and CD4 Values during EC Status
Median HIV-RNA during the time of EC was generally low for
all definitions varying from 35–903 copies/ml and median CD4
levels high at .500 cells/mm3 (Table 5). There was strong
evidence of CD4 loss during this EC period, however, for at least 5
of the 10 definitions considered. For the remaining definitions,
Table 2. Number of elite controllers (EC), their proportion, and demographic characteristics applying the CASCADE dataset to 10
definitions of EC found in the literature.
Def.
EC
(n)
Non-EC
(n)
Unknown{
(n)
EC
Proportion
Best
Estimate`
n (%)
EC
Proportion
Minimum
Estimate
n (%)
Seroconversion
Age (Median)
Male
(%)
MSM
(%)
IDU
(%)
MSW
(%)
ECs
Non
ECs ECs
Non
ECs ECs
Non
ECs ECs
Non
ECs ECs
Non
ECs
A 282 20951 4396 1.33 1.10 32 31 74 78 53 57 11 11 32 27
B 495 19568 5566 2.47 1.93 32 31 79 78 59 56 15 11 23 28
C 827 19236 5566 4.12 3.23 32 31 74 78 54 56 11 11 31 27
D 1416 16964 7249 7.70 5.52 30 31 67 79 49 58 11 10 36 27
E 174 17160 8295 1.00 0.68 33 31 75 78 52 57 13 10 30 28
F 95 17239 8295 0.55 0.37 32 31 63 78 37 57 18 10 38 28
G 392 16891 8346 2.27 1.53 32 31 76 77 55 56 12 11 30 28
H 146 10899 14584 1.32 0.57 31 30 74 77 47 55 18 13 29 27
I 10 6694 18925 0.15 0.04 26 29 80 77 30 53 60 18 0 25
J 47 6554 19028 0.71 0.18 31 29 74 77 34 53 28 17 30 25
{Individuals in the cohort without adequate follow-up or number of HIV-RNA measurements to classify them as EC or non-EC.
`Based on number of seroconverters whose EC status could be determined.
HIV risk groups: MSM: Men who have sex with men; IDU: Injection drug users; MSW: Heterosexual contact.
Assuming all individuals with unknown EC status are non-EC.
A: HIV-positive$6 months, with$2 consecutive HIV-RNA,75 copies/ml; B: HIV- positive $1 year, with $1 HIV-RNA,50 copies/ml, C: HIV- positive $1 year, with $1
HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3 HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning
$12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months with no previous blips $1000 copies/ml, G:HIV- positive $2
years, with $2 HIV-RNA ,75 copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-RNA ,500 copies/ml, I: HIV- positive $10 years, with all measured HIV-RNA
,50 copies/ml, J: HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.t002
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slopes were either level (no strong evidence of CD4 loss) or
otherwise with a statistically significant positive slope. Such
positive slopes are likely due to short follow-up, chance, or
possibly informative censoring, as follow-up is censored for those
with a negative slope once ART is initiated [26]. Median HIV-
RNA, CD4 values and CD4 slopes during EC status excluding
counts within 6 months of seroconversion showed similar results
(data not shown).
HIV-RNA and CD4 Values during Total ART-naı¨ve Follow-
up
As expected, throughout available ART-naı¨ve follow-up,
median HIV-RNA values were generally higher, and CD4 counts
lower than those considering only the time spent as EC.
Nevertheless, median HIV-RNA throughout ART-naı¨ve follow-
up was low, ,200 copies/ml for most definitions, and median
CD4 values were .500 cells/mm3 for all definitions (Table 5).
Table 3. Two-way overlap of 10 definitions of elite control found in the literature applied to the CASCADE dataset.
Def. A, n (%) B, n (%) C, n (%) D, n (%) E, n (%) F, n (%) G, n (%) H, n (%) I, n (%) J, n (%) Total
A – 195 (39) 279 (34) 275 (19) 174 (100) 95 (100) 250 (64) 113 (77) 4 (40) 35 (74) 282
B 195 (69) – 495 (60) 341 (24) 119 (68) 45 (47) 286 (73) 94 (64) 10 (100) 36 (77) 495
C 279 (99) 495 (100) – 542 (38) 174 (100) 95 (100) 392 (100) 133 (91) 10 (100) 42 (89) 827
D 275 (98) 341 (69) 542 (66) – 174 (100) 95 (100) 354 (90) 146 (100) 4 (40) 41 (87) 1416
E 174 (62) 119 (24) 174 (21) 174 (12) – 95 (100) 165 (42) 95 (65) 3 (30) 31 (66) 174
F 95 (34) 45 (9) 95 (11) 95 (7) 95 (55) – 91 (23) 53 (36) 3 (30) 25 (53) 95
G 250 (89) 286 (58) 392 (47) 354 (25) 165 (95) 91 (96) – 125 (86) 6 (60) 41 (87) 392
H 113 (40) 94 (19) 133 (16) 146 (10) 95 (55) 53 (56) 125 (32) – 3 (30) 29 (62) 146
I 4 (1) 10 (2) 10 (1) 4 (0) 3 (2) 3 (3) 6 (2) 3 (2) – 6 (13) 10
J 35 (12) 36 (7) 42 (5) 41 (3) 31 (18) 25 (26) 41 (10) 29 (20) 6 (60) – 47
Total 282 495 827 1416 174 95 392 146 10 47
Example: 95 seroconverters were classified as EC by definition F of whom 25 (26%) were classified as EC by definition J. Conversely, of 47 seroconverters classified as EC
by definition J, 25 (53%) were classified as EC by definition F.
A: HIV-positive$6 months, with$2 consecutive HIV-RNA,75 copies/ml; B: HIV- positive $1 year, with $1 HIV-RNA,50 copies/ml, C: HIV- positive $1 year, with $1
HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3 HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning
$12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months with no previous blips $1000 copies/ml, G:HIV- positive $2
years, with $2 HIV-RNA ,75 copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-RNA ,500 copies/ml, I: HIV- positive $10 years, with all measured HIV-RNA
,50 copies/ml, J: HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.t003
Table 4. Estimated hazard ratios comparing non-elite controllers (EC) and unknown to EC for time from estimated HIV
seroconversion to a composite endpoint of AIDS, Death, ART, or CD4,350 cells/mm3 restricting entry to the risk set at 10 years
post seroconversion using the CASCADE dataset applied to 10 definitions of EC found in the literature.
Def.
EC evaluated (experiencing
composite endpoint) n (n){{
HR for time to composite
endpoint{ (95% CI)
% (IQR) ART-naı¨ve follow-up
time classified as EC
A 46 (4) 12.5 (4.7, 33.6) 100 (78–100)
B 53 (11) 4.6 (2.5, 8.3)` 100 (78–100)
C 86 (18) 4.8 (3.0, 7.7)` 99 (72–100)
D 134 (35) 4.0 (2.8, 5.7)` 97 (71–100)
E 36 (2) 19.0 (4.7, 76.4) 100 (78–100)
F 26 (5) 15.3 (3.8, 61.3) 92 (66–100)
G 60 (9) 7.5 (3.9, 14.5)` 100 (86–100)
H 56 (22) 2.9 (1.9, 4.4)` 100 (75–100)
I 4 (1) 3.4 (0.5, 24.0) 100 (100–100)
J 35 (3) 13.2 (4.2, 41.3) 100 (98–100)
{{Number of Elites making it to 10 years follow up without experiencing composite endpoint and number subsequently experiencing composite endpoint.
{Hazard ratios comparing ECs to Non-ECs (including those with unknown EC status) allowing for late entry at 10 years. For each definition, p-values were obtained from
unadjusted log-rank test for time to composite endpoint and were all highly significant p,0.001.
`Statistically different HRs compared to definition E, F, and A from 1000 bootstrap replicates. No definitions were statistically different from definition J at a= 0.05.
A: HIV-positive$6 months, with$2 consecutive HIV-RNA,75 copies/ml; B: HIV- positive $1 year, with $1 HIV-RNA,50 copies/ml, C: HIV- positive $1 year, with $1
HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3 HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning
$12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months with no previous blips $1000 copies/ml, G:HIV- positive $2
years, with $2 HIV-RNA ,75 copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-RNA ,500 copies/ml, I: HIV- positive $10 years, with all measured HIV-RNA
,50 copies/ml, J: HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.t004
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Of note, however, CD4 slopes during total ART-naı¨ve follow-
up were significantly negative (a= 0.05) for all but one definition.
HIV-RNA and CD4 values and CD4 slopes showed consistent
results when CD4 values within 6 months of seroconversion were
excluded (data not shown).
Discussion
Using the large size of the CASCADE dataset we were able to
provide reliable estimates of the proportion likely to be elite
controllers in an HIV-positive population. Our findings confirm
that, by whichever definition, elite control is a rare phenotype
likely to comprise around 1% of individuals. This is in line with
estimates reported by others [7,8,23] although it should be noted
that the choice of denominator may distort the proportion (for
example, considering all individuals regardless of their length of
follow-up or HIV infection duration will tend to under-estimate
this proportion of ECs). Interestingly, we also find evidence that
ECs may eventually lose control of viraemia.
Definitions A, E, F and J which require low consecutive or a
high proportion of low HIV-RNA measurements are best at
capturing individuals with the slowest disease progression. When
restricting the dataset to those with 10 years of follow-up,
definitions A, E and F and J demonstrated the lowest hazard of
AIDS, Death, ART or CD4,350 cells/mm3 compared to
definitions with single measurements or higher levels of viremia.
Definition J, with the longest follow-up of 10 years was not
significantly different from all other definitions, although this is
likely due to low numbers of individuals classified by this
definition.
The proportion classified as EC varied according to each
definition, with definition D, requiring an HIV-RNA threshold of
,2000 copies/ml, classifying the greatest proportion as EC. This
definition performed particularly poorly overall with the highest
median HIV-RNA and fastest CD4 cell loss while classified as EC
and during ART naı¨ve follow-up. Given that the lower limit for
available assays has been less than 1000 copies/ml for at least 10
years, inclusion of 2000 copies/ml limit is justifiably termed ‘‘viral
controllers’’ rather than EC. The requirement of only one HIV-
RNA measurement below a certain threshold (B and C) also
resulted in relatively high proportions of EC (2.47% and 4.12%,
respectively), agreeing with studies previously reporting propor-
tions of individuals with $1 HIV-RNA undetectable [27,28], and
suggesting that one undetectable measurement is insufficient in
defining EC status. HIV-RNA values were relatively high during
EC period for both definitions with the upper quartile experienc-
ing HIV-RNA values .8000 copies/ml. Similarly, even while
classified as EC, CD4 cell counts were significantly declining.
Thus, the use of at least two HIV-RNA counts results in more
Figure 1. Total ART-naı¨ve follow-up time spent as an elite controller for 4 of the best performing definitions: a) A , b) E , c) F ,and
d) J using the CSCADE dataset. A: HIV-positive $6 months, with $2 consecutive HIV-RNA ,75 copies/ml; E: HIV- positive $1 year, with $3
consecutive HIV-RNA ,75 copies/ml spanning $12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning $12
months with no previous blips $1000 copies/ml, J: HIV- positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.g001
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robust measures of stable viraemia and thus captures individuals
with lower risk of disease progression.
In contrast, definitions I, J, E and F had the lowest proportion
classified as EC varying between 0.15–1.00%. While this is
expected for definitions that required ten years of follow-up (I and
J), definition E and F, requiring only one year follow-up seemed to
capture an equally rare group. The proportion of EC according to
definition F was much lower than for definition E, indicating that
inclusion of a criterion and threshold for viral blips, as defined by
spikes in viral replication and subsequently maintaining control,
does impact the group of individuals captured by the definition.
This is consistent with studies suggesting that blips are not
uncommon among elite controllers. [7,29] In addition to selecting
for a rare group, definitions E, F and J also selected groups with
the lowest risk for the composite outcome, suggesting that these
definitions capture a rare and extreme group on the clinical
spectrum of HIV infection. Unsurprisingly, definition I led to the
classification of the smallest proportion (0.15%) of EC. This is the
most stringent definition as all HIV-RNA measurements needed to
have been quantified by assays with a lower limit of detection ,50
copies/ml for $10 years. The denominator from which this
population has been drawn is, by definition, limited to the most
recent period when routinely used assays had such low detection
limits. Median HIV-RNA and CD4 values for those classified as
EC by this definition are based on few measurements and are,
therefore, unreliable.
Interestingly, a greater duration of follow-up did not necessarily
lead to a more clinically-extreme group of individuals being
identified, as definition E and J performed similarly, in spite of E
requiring only 1 year of follow-up. There were 16 individuals
classified by J but not by E. Six of these 16 were known to have
naı¨ve HIV-RNAs between 75 and 400 copies/ml, while HIV-
RNA for the remaining 10 individuals were measured using assays
with a 400 copies/ml lower detection threshold. Of 143
individuals classified as EC by E but not by J, 113 had ,10
years of naı¨ve follow-up. It may, therefore, be that overlap could
be greater had all individuals been measured for the same duration
with similar assays. In addition, median CD4 counts, HIV-RNA
levels and CD4 slopes during the ART-naı¨ve period were also
similar for these definitions. This observation may have important
implications for the design of future studies, as it seems to suggest
that stringent definitions requiring only one year of follow-up, with
consecutive undetectable HIV-RNA measurements, can identify
an extreme group comparable to that identified by definitions
requiring much longer follow-up and higher HIV-RNA threshold.
There is, therefore, potential to sampling of participants in such
studies from a much wider cohort of individuals.
It is important to note that, despite the fairly low levels of
viraemia in individuals classified as EC over extended periods,
there was strong evidence of CD4 cell loss, the exception being
those classified as EC by definition I, which was based on relatively
few measurements. Whether true LTNP status exists remains
unknown [30,31]. Our findings lead us to conclude, however, that
this is unlikely among elite controllers.
Our study has several strengths. First, the large size of our
cohort allows us to make reliable comparisons of different
definitions of such a rare group of individuals. Second, the
availability of seroconversion information allows for a meaningful
assessment of time to clinical outcomes to be made. Finally, and
most importantly, until now, examination of CD4 and HIV-RNA
changes in studies has been restricted to the period in which HIV-
positive individuals fulfil the respective definition. [29,32,33] Due
to the detailed information available to us, we were able to study
evolution of both these markers over an extended period of follow-
up, beyond the duration of EC as defined.
The main limitation to this study is for each definition, the
number of individuals with unknown EC classification varied
which could have introduced bias in proportion estimates. This is
most evident in definition J, requiring .2 HIV-RNA measure-
ments and at least 10 years of follow-up with .19,000 individuals
Table 5. HIV-RNA and CD4 values and estimated CD4 slope during elite control (EC), and throughout ART-naı¨ve follow-up using
the CASCADE dataset applied to 10 definitions of EC found in the literature.
Def. During Elite Control During ART-naı¨ve follow-up
HIV-RNA value CD4 Value CD4 slope{ (95% CI) HIV-RNA value CD4 Value CD4 slope{ (95% CI)
A 50 (35, 276) 675 (454, 877) 0.04 (0.01, 0.08) 66 (35, 495) 654 (441, 840) 20.09 (20.12, 20.06)`
B 425 (35, 11641) 573 (409, 792) 20.16 (20.19, 20.12)` 1043 (89, 13000) 548 (404, 751) 20.28 (20.30, 20.25)`
C 354 (50, 8700) 596 (427, 796) 20.18 (20.21, 20.15)` 660 (75, 11066) 567 (415, 764) 20.31 (20.34, 20.29)`
D 903 (287, 1863) 615 (478, 789) 20.27 (20.29, 20.25)` 1274 (370, 3304) 590 (451, 756) 20.43 (20.45, 20.41)`
E 50 (35, 81) 699 (528, 922) 0.06 (0.01, 0.10) 50 (35, 165) 681 (527, 909) 20.06 (20.10, 20.02)
F 50 (35, 50) 839 (654, 1070) 0.05 (20.00, 0.11) 50 (35, 77) 796 (629, 1020) 20.08 (20.13, 20.03)
G 113 (49, 1197) 644 (439, 824) 20.06 (20.09, 20.03)` 176 (50, 2160) 625 (438, 806) 20.15 (20.18, 20.13)`
H 76 (35, 283) 697 (541, 879) 20.09 (20.12, 20.05)` 89 (35, 356) 687 (530, 879) 20.23 (20.26, 20.20)`
I 35 (1, 35) 583 (575, 905) 20.07 (20.24, 0.09) 35 (1, 35) 583 (575, 905) 20.05 (20.21, 0.11)
J 50 (35, 127) 783 (628, 970) 20.03 (20.09, 0.02) 50 (35, 169) 740 (583, 970) 20.11 (20.16, 20.06)`
Note- all values unless otherwise stated are median (IQR).
{CD4 slope modelled on the square root scale with linear mixed models, specific p-values for CD4 slope and median number of CD4 measurements are presented in
Table S1.
`CD4 slope highly significant p,0.001.
T- Number of total CD4 and HIV-RNA measurements A: HIV-positive $6 months, with $2 consecutive HIV-RNA ,75 copies/ml; B: HIV- positive $1 year, with $1 HIV-
RNA ,50 copies/ml, C: HIV- positive $1 year, with $1 HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3 HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year,
with $3 consecutive HIV-RNA ,75 copies/ml spanning $12 months F: HIV- positive $1 year, with $3 consecutive HIV-RNA ,75 copies/ml spanning$12 months with
no previous blips $1000 copies/ml, G:HIV- positive $2 years, with $2 HIV-RNA ,75 copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-RNA ,500 copies/
ml, I: HIV- positive $10 years, with all measured HIV-RNA ,50 copies/ml, J: HIV-positive $10 years, with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
doi:10.1371/journal.pone.0086719.t005
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with either insufficient follow-up or number of HIV-RNA
measurements. To examine the impact of missing data on this,
for each definition we classified individuals with inadequate
information (insufficient number of HIV-RNA measurements or
follow-up requirements specified by the definition) as EC and then
as non-EC. The proportion of EC; however, may theoretically
range from 0.04, if all unknowns are classified as non-EC, to 74%,
if all unknowns are classified as EC (data not shown) indicating the
difficulties with estimating the true proportion of this group in the
presence of missing data. In spite of these possible limitations, our
study highlights important differences captured by different EC
definitions.
In conclusion, identification of a rare and extreme group may
be possible even with definitions requiring a relatively short period
of follow-up. We have shown that definitions requiring 6 months
or more of follow-up with consecutive measurements requiring
HIV-RNA #75 copies/ml preform just as well as definitions
requiring $10 years follow-up with HIV-RNA measured using
assays with a higher detection limit. Although Definition E
preforms best overall in terms of percent classified, time to
composite endpoint, percent of naı¨ve follow-up time spent as EC,
HIV-RNA, and CD4 decline, definition A (2 consecutive HIV-
RNA ,75 copies/ml over 6 months), F (similar to E, but not
allowing for blips above 1000 copies/ml) and J (10 years of follow-
up with 90% HIV-RNA,400 copies/ml) also have their merits. It
is unlikely, however, that elite control is an indefinite state, and
that the few HIV-positive individuals who spontaneously control
HIV replication may eventually need treatment or develop AIDS
given the on-going, albeit slow, CD4 cell loss. However, ECs are
much less likely to progress to clinical disease compared with non-
ECs, and a better understanding of the mechanisms that lead to
such control over extended periods may lead to new therapeutic
strategies or the development of HIV vaccines.
Supporting Information
Table S1 Number of HIV-RNA and CD4 measurements
during elite control and ART naı¨ve follow-up, time from
SC to first HIV-RNA and number of HIV-RNA measure-
ments within 6 months of HIV positive test date using
the CASCADE dataset from 10 definitions found in the
literature. Note- all values unless otherwise stated are median
(IQR) {CD4 slope modelled on the square root scale with linear
mixed models A: HIV-positive $6 months, with $2 consecutive
HIV-RNA ,75 copies/ml; B: HIV- positive $1 year, with $1
HIV-RNA ,50 copies/ml, C: HIV- positive $1 year, with $1
HIV-RNA ,75 copies/ml, D: HIV- positive $1 year, with $3
HIV-RNA ,2000 copies/ml, E: HIV- positive $1 year, with $3
consecutive HIV-RNA ,75 copies/ml spanning $12 months F:
HIV- positive $1 year, with $3 consecutive HIV-RNA ,75
copies/ml spanning $12 months with no previous blips $1000
copies/ml, G:HIV- positive $2 years, with $2 HIV-RNA ,75
copies/ml, H: HIV- positive $5 years, with $5 consecutive HIV-
RNA ,500 copies/ml, I: HIV- positive $10 years, with all
measured HIV-RNA ,50 copies/ml, J: HIV-positive $10 years,
with $90% of HIV-RNA ($2 HIV-RNA ever) ,400 copies/ml.
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